A Recombinant Plasmodium vivax Apical Membrane Antigen-1 to Detect Human Infection in Iran
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In Iran, Plasmodium vivax is responsible for more than 80% of the infected cases of malaria per year. Control interventions for vivax malaria in humans rely mainly on developed diagnostic methods. Recombinant P. vivax apical membrane antigen-1 (rPvAMA-1) has been reported to achieve designing rapid, sensitive, and specific molecular diagnosis. This study aimed to perform isolation and expression of a rPvAMA-1, derived from Iranian patients residing in an endemic area. Then, the diagnostic efficiency of the characterized Iranian PvAMA-1 was assessed using an indirect ELISA method. For this purpose, a partial region of AMA-1 gene was amplified, cloned, and expressed in pET32a plasmid. The recombinant His-tagged protein was purified and used to coat the ELISA plate. Antibody detection was assessed by indirect ELISA using rPvAMA-1. The validity of the ELISA method for detection of anti-P. vivax antibodies in the field was compared to light microscopy on 84 confirmed P. vivax patients and compared to 84 non-P. vivax infected individuals. The ELISA cut-off value was calculated as the mean+2SD of OD values of the people living in malaria endemic areas from a south part of Iran. We found a cut-off point of OD=0.311 that showed the best correlation between the sera confirmed with P. vivax infection and healthy control sera. A sensitivity of 81.0% and specificity of 84.5% were found at this cut off titer. A good degree of statistical agreement was found between ELISA using rPvAMA-1 and light microscopy (0.827) by Kappa analysis.
Abstract
In Iran, Plasmodium vivax is responsible for more than 80% of the infected cases of malaria per year. Control interventions for vivax malaria in humans rely mainly on developed diagnostic methods. Recombinant P. vivax apical membrane antigen-1 (rPvAMA-1) has been reported to achieve designing rapid, sensitive, and specific molecular diagnosis. This study aimed to perform isolation and expression of a rPvAMA-1, derived from Iranian patients residing in an endemic area. Then, the diagnostic efficiency of the characterized Iranian PvAMA-1 was assessed using an indirect ELISA method. For this purpose, a partial region of AMA-1 gene was amplified, cloned, and expressed in pET32a plasmid. The recombinant His-tagged protein was purified and used to coat the ELISA plate. Antibody detection was assessed by indirect ELISA using rPvAMA-1. The validity of the ELISA method for detection of anti-P. vivax antibodies in the field was compared to light microscopy on 84 confirmed P. vivax patients and compared to 84 non-P. vivax infected individuals. The ELISA cut-off value was calculated as the mean+2SD of OD values of the people living in malaria endemic areas from a south part of Iran. We found a cut-off point of OD=0.311 that showed the best correlation between the sera confirmed with P. vivax infection and healthy control sera. A sensitivity of 81.0% and specificity of 84.5% were found at this cut off titer. A good degree of statistical agreement was found between ELISA using rPvAMA-1 and light microscopy (0.827) by Kappa analysis.
참고문헌 (29)
- Snow RW, "The global distribution of clinical episodes of Plasmodium falciparum malaria", Nature, 434, pp.214~217 (2005)
- Greenwood B, "Malaria in 2002", Nature, 415, pp.670~672 (2002)
- Hay SI, "The global distribution and population at risk of malaria: Past, present, and future", Lancet Infect Dis, 4, pp.327~336 (2004)
- Mendis K, "The neglected burden of Plasmodium vivax malaria", Am J Trop Med Hyg, 64(1-2 suppl), pp.97~106 (2001)
- Edrissian GH, "Malaria in Iran: past and present situation", Iranian J Parasitol, 1, pp.1~14 (2006)
- Soler E, "Preparation of recombinant vaccines", Biotechnol Annu Rev, 13, pp.65~94 (2007)
- Giraldo MA, "Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection", Vaccine, 28, pp.7~13 (2009)
- Voller A, "Methods of measuring the immunological response to Plasmodia, In Immunology and Immunisation. Malaria. Vol. 3", pp.67~109 (1980), Academic Press
- Voller A, "New serological test for malaria antibodies", Br Med J, 1, pp.659~661 (1975)
- Rodrigues MH, "Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1", Int J Parasitol, 35, pp.185~192 (2005)
- "Serological testing in malaria", Bull World Health Organ, 50, pp.527~535 (1974)
- Altman DG, "Practical statistics for medical research" (2001), Chapman & Hall
- Babakhan L, "Rapid detection of Leishmania infantum infection in dogs: A comparative study using fast agglutination screening test (FAST) and direct agglutination test (DAT) in Iran", Parasitol Res, 105, pp.717~720 (2009)
- James S, "Malaria vaccine development: Status report", Nature Med, (Suppl) (2000)
- Vekemans J, "Plasmodium falciparum malaria vaccines in development", Expert Rev Vaccines, 7, pp.223~240 (2008)
- Morais CG, "Antibodies to Plasmodium vivax apical membrane antigen 1: Persistence and correlation with malaria transmission intensity", Am J Trop Med Hyg, 75, pp.582~587 (2006)
- Mahanty S, "Progress in the development of recombinant and synthetic blood-stage malaria vaccines", J Exp Biol, 206(Pt 21), pp.3781~3788 (2003)
- Herrera S, "An update on the search for a Plasmodium vivax vaccine", Trends Parasitol, 23, pp.122~128 (2007)
- Bueno LL, "Plasmodium vivax recombinant vaccine candidate AMA-1 plays an important role in adaptive immune response eliciting differentiation of dendritic cells", Vaccine, 27, pp.5581~5588 (2009)
- Remarque EJ, "Apical mem-brane antigen 1: A malaria vaccine candidate in review", Trends Parasitol, 24, pp.74~84 (2008)
- Thomas AW, "The Fab fragments of monoclonal IgG to a merozoite surface antigen inhibit Plasmodium knowlesi invasion of erythrocytes", Mol Biochem Parasitol, 13, pp.187~199 (1984)
- Deans JA, "Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi", Clin Exp Immunol, 49, pp.297~309 (1982)
- Wickramarachchi T, "Natural human antibody responses to Plasmodium vivax apical membrane antigen 1 under low transmission and unstable malaria conditions in Sri Lanka", Infect Immun, 74, pp.798~801 (2006)
- SeraKIM, "ELISA detection of vivax malaria with recombinant multiple stage-specific antigens and its application to survey of residents in endemic areas", The Korean Journal of Parasitology, 41(4), pp.203~207 (2003), 대한기생충학회
- Mehrizi AA, "IgG subclasses pattern and high-avidity antibody to the C-terminal region of merozoite surface protein 1 of Plasmodium vivax in an unstable hypoendemic region in Iran", Acta Trop, 112, pp.1~7 (2009)
- Thomas AW, "High prevalence of natural antibodies against Plasmodium falciparum 83-kilodalton apical membrane antigen (PF83", AMA-1) as detected by capture-enzyme-linked immunosorbent assay using full-length baculovirus recombinant PF83, Am J Trop Med Hyg, pp.1994, 51[DOI]
- Nair M, "Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen1 (AMA1)", J Mol Biol, 322, pp.741~753 (2002)
- Holder AA, "Preventing merozoite invasion of erythrocytes, In Malaria vaccine development: A multi-immune response approach", pp.77~104 (1996), American Society of Microbiology
- Krotoski WA, "Discovery of the hypnozoite and a new theory of malarial relapse", Trans R Soc Trop Med Hyg, 79, pp.1~11 (1985)